# A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

> **NCT06585241** · PHASE4 · RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 1144 (estimated)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1273 Variant-containing Formulation

## Key facts

- **NCT ID:** NCT06585241
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1144 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585241, "A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06585241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*